Latest Revenue Growth News

Veris Limited confirms a strong turnaround in FY25 with a $2 million profit before tax and 5% revenue growth, driven by strategic transformation and a major Victorian rail contract.

Hiremii Limited reported a 4.4% revenue increase in Q4 FY25 alongside positive operating cash flow, while accelerating commercialisation of its proprietary AI recruitment platform and expanding through a key acquisition.

ReadCloud Limited reported a robust 35% increase in cash receipts for the June quarter, driven by strong growth in its VET-in-Schools segment and disciplined cost management. The company forecasts positive underlying EBITDA and operating cash flow for FY25, positioning itself for accelerated growth in 2026.

Aerometrex has completed a strategic review that delivers $2 million in cost savings and initiates data monetisation, positioning the company for accelerated growth in FY26.

Talius Group has reported a net profit of $0.37 million for Q2 2025, driven by a 6% increase in subscriptions and strategic partnerships that expand its market reach in aged care technology.

Elsight Limited reports record-breaking revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market opportunities, positioning the company for profitability later this year.

Austco Healthcare reports robust FY25 growth with revenue climbing over 37% and EBITDA soaring by more than 54%, fueled by strong organic performance and key acquisitions.

One Click Group Limited has outpaced its entire July 2024 revenue within the first 18 days of July 2025, defying a broader decline in tax lodgements and showcasing strong customer loyalty.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

Credit Clear Limited has outperformed its FY25 financial guidance with a 76% rise in underlying EBITDA and secured exclusive digital debt recovery contracts with leading insurers, setting a robust stage for FY26 growth.

Microba Life Sciences reports strong Q4 FY25 growth driven by record microbiome test sales and clinician adoption in Australia and the UK, while advancing its therapeutics pipeline and targeting regional break-even in FY26.

Microba Life Sciences reports record Q4 FY25 microbiome test sales in Australia and the UK, underpinned by landmark clinical studies and a $14.5 million capital raise. The company is transitioning away from legacy products to focus on high-value diagnostics, positioning for sustained growth in FY26.